Janux Therapeutics (JANX) Current Deferred Revenue (2020 - 2026)

Janux Therapeutics (JANX) has 6 years of Current Deferred Revenue data on file, last reported at $37.6 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $37.6 million in Q1 2026; TTM through Mar 2026 was $37.6 million, a N/A change from a year earlier, with the FY2023 full-year figure at $1.7 million, down 68.46% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $37.6 million, up from $94000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for JANX reached as high as $37.6 million in Q1 2026 and fell as low as $94000.0 in Q2 2024.
• Historically, Current Deferred Revenue has averaged $6.9 million across 4 years, with a median of $4.9 million in 2023.
• Across the five-year window, Current Deferred Revenue advanced 12.2% in 2022 and sank 98.24% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $5.4 million in 2022, then plunged by 68.46% to $1.7 million in 2023, then plunged by 94.49% to $94000.0 in 2024, then surged by 39890.43% to $37.6 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $37.6 million in Q1 2026, $94000.0 in Q2 2024, and $972000.0 in Q1 2024.